1970 related articles for article (PubMed ID: 20647199)
1. Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Stone JH; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Turkiewicz A; Tchao NK; Webber L; Ding L; Sejismundo LP; Mieras K; Weitzenkamp D; Ikle D; Seyfert-Margolis V; Mueller M; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh KA; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Specks U;
N Engl J Med; 2010 Jul; 363(3):221-32. PubMed ID: 20647199
[TBL] [Abstract][Full Text] [Related]
2. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Viviano L; Tchao NK; Phippard DJ; Asare AL; Lim N; Ikle D; Jepson B; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Mueller M; Sejismundo LP; Mieras K; Stone JH;
N Engl J Med; 2013 Aug; 369(5):417-27. PubMed ID: 23902481
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Viviano L; Ding L; Sejismundo LP; Mieras K; Iklé D; Jepson B; Mueller M; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Stone JH;
Arthritis Rheum; 2013 Sep; 65(9):2441-9. PubMed ID: 23754238
[TBL] [Abstract][Full Text] [Related]
5. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Ding L; Iklé D; Villareal M; Lim N; Brunetta P; Fervenza FC; Monach PA; Stone JH;
Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
8. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.
Pagnoux C; Mahr A; Hamidou MA; Boffa JJ; Ruivard M; Ducroix JP; Kyndt X; Lifermann F; Papo T; Lambert M; Le Noach J; Khellaf M; Merrien D; Puéchal X; Vinzio S; Cohen P; Mouthon L; Cordier JF; Guillevin L;
N Engl J Med; 2008 Dec; 359(26):2790-803. PubMed ID: 19109574
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis.
Langford CA
Clin Exp Immunol; 2011 May; 164 Suppl 1(Suppl 1):31-4. PubMed ID: 21447129
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial.
Keogh KA; Ytterberg SR; Fervenza FC; Carlson KA; Schroeder DR; Specks U
Am J Respir Crit Care Med; 2006 Jan; 173(2):180-7. PubMed ID: 16224107
[TBL] [Abstract][Full Text] [Related]
11. Rituximab (MABTHERA) and severe polyangiitis. An option for patients informed of the uncertainties.
Prescrire Int; 2015 Jun; 24(161):145-8. PubMed ID: 26436161
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of ANCA-associated vascularitides].
Guillevin L; Pagnoux C
Presse Med; 2007 May; 36(5 Pt 2):922-7. PubMed ID: 17408912
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.
PLoS One; ; . PubMed ID: 29016646
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
